MA30871B1 - Triazoles bicycliques a titre de modulateurs de proteines kinases - Google Patents

Triazoles bicycliques a titre de modulateurs de proteines kinases

Info

Publication number
MA30871B1
MA30871B1 MA31849A MA31849A MA30871B1 MA 30871 B1 MA30871 B1 MA 30871B1 MA 31849 A MA31849 A MA 31849A MA 31849 A MA31849 A MA 31849A MA 30871 B1 MA30871 B1 MA 30871B1
Authority
MA
Morocco
Prior art keywords
modulators
protein kinases
bicyclic
bicyclic triazoles
triazoles
Prior art date
Application number
MA31849A
Other languages
English (en)
Inventor
Pierre-Yves Bounaud
Christopher Ronald Smith
Elizabeth Anne Jefferson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of MA30871B1 publication Critical patent/MA30871B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION FOURNIT DES MODULATEURS DE PROTÉINE KINASE DE TRIAZOLE BICYCLIQUE, ET DES PROCÉDÉS POUR UTILISER CES COMPOSÉS POUR TRAITER DES MALADIES FAVORISÉES PAR UNE ACTIVITÉ DE KINASE.
MA31849A 2006-10-23 2009-05-07 Triazoles bicycliques a titre de modulateurs de proteines kinases MA30871B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
MA30871B1 true MA30871B1 (fr) 2009-11-02

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31849A MA30871B1 (fr) 2006-10-23 2009-05-07 Triazoles bicycliques a titre de modulateurs de proteines kinases

Country Status (25)

Country Link
US (1) US8507489B2 (fr)
EP (1) EP2084162B1 (fr)
JP (1) JP5378222B2 (fr)
KR (1) KR20090071612A (fr)
AR (1) AR063520A1 (fr)
AU (1) AU2007309149C1 (fr)
BR (1) BRPI0717320A2 (fr)
CA (1) CA2667428A1 (fr)
CO (1) CO6190620A2 (fr)
CR (1) CR10803A (fr)
DK (1) DK2084162T3 (fr)
EA (1) EA200970403A1 (fr)
ES (1) ES2393130T3 (fr)
IL (1) IL197958A0 (fr)
MA (1) MA30871B1 (fr)
MX (1) MX2009004059A (fr)
NO (1) NO20091618L (fr)
NZ (1) NZ575336A (fr)
PE (1) PE20080893A1 (fr)
PL (1) PL2084162T3 (fr)
PT (1) PT2084162E (fr)
SV (1) SV2009003235A (fr)
TN (1) TN2009000142A1 (fr)
TW (1) TW200835492A (fr)
WO (1) WO2008051808A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (fr) 2008-09-19 2010-03-24 Institut Curie Récepteur TYRO3 de la tyrosine kinase en tant que cible thérapeutique dans le traitement d'une tumeur de la vessie
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
EA030141B1 (ru) 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP2015512447A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害薬の組合せおよびその使用
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (fr) 2012-12-10 2014-06-19 Abbvie Inc. Composés triazinones
US9364405B2 (en) 2013-03-13 2016-06-14 Avon Products, Inc. Tyrosinase inhibitors
WO2014158943A1 (fr) * 2013-03-13 2014-10-02 Avon Products, Inc Inhibiteurs de tyrosinase
MX2015011438A (es) * 2013-03-13 2016-02-03 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina.
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
WO2014174478A1 (fr) 2013-04-26 2014-10-30 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
WO2014180182A1 (fr) * 2013-05-10 2014-11-13 江苏豪森药业股份有限公司 Dérivé de [1,2,4]-triazole-[4,3-a]-pyridine, procédé de préparation correspondant ou application médicale correspondante
WO2017049711A1 (fr) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 Dérivé de quinoléine, composition pharmaceutique, méthode de préparation et utilisation de celui-ci

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
EP0228061A3 (fr) 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Composés céphem
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083139A1 (fr) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibiteurs de l'activite d'akt
US6960584B2 (en) * 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
WO2004058769A2 (fr) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs des proteine kinases
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
CA2573573A1 (fr) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Modulateurs heterocycliques a cycles fusionnes pour les kinases
ES2355923T3 (es) 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
MX2007007797A (es) 2004-12-27 2007-08-23 Alcon Inc Analogo de aminopirazina para tratar glaucoma y otras enfermedades mediadas por rho cinasa.

Also Published As

Publication number Publication date
DK2084162T3 (da) 2012-10-01
PL2084162T3 (pl) 2013-01-31
AU2007309149A1 (en) 2008-05-02
TW200835492A (en) 2008-09-01
EA200970403A1 (ru) 2009-10-30
WO2008051808A3 (fr) 2008-07-24
PT2084162E (pt) 2012-10-09
SV2009003235A (es) 2009-10-15
PE20080893A1 (es) 2008-08-26
ES2393130T3 (es) 2012-12-18
NO20091618L (no) 2009-05-22
NZ575336A (en) 2012-04-27
IL197958A0 (en) 2009-12-24
AU2007309149B2 (en) 2012-09-06
AR063520A1 (es) 2009-01-28
WO2008051808A2 (fr) 2008-05-02
US8507489B2 (en) 2013-08-13
MX2009004059A (es) 2009-04-27
EP2084162B1 (fr) 2012-09-12
CA2667428A1 (fr) 2008-05-02
EP2084162A2 (fr) 2009-08-05
CR10803A (es) 2009-06-16
JP2010507578A (ja) 2010-03-11
BRPI0717320A2 (pt) 2013-10-22
AU2007309149C1 (en) 2013-04-04
TN2009000142A1 (en) 2010-10-18
JP5378222B2 (ja) 2013-12-25
KR20090071612A (ko) 2009-07-01
CO6190620A2 (es) 2010-08-19
US20090258855A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
MA30871B1 (fr) Triazoles bicycliques a titre de modulateurs de proteines kinases
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
IL272273A (en) Antibodies against 38CD for the treatment of multiple myeloma
TW200801008A (en) Protein kinase inhibitors
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200970738A1 (ru) Ингибиторы активности akt
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
CY1116295T1 (el) Αναστολεις της κινασης τυροσινης toy bruton
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
TW200626068A (en) Active compounds for seed treatment
MX2009011210A (es) Inhibidores de mcl1 de indol 7-no sustituido.
IN2014KN02886A (fr)
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
EA201170831A1 (ru) Аминопиразольное соединение
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
NO20090608L (no) Tyrosinkinaseinhibitorer
IL193479A0 (en) Modulators of muscarinic receptors
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
UY30666A1 (es) Trizoles biciclicos como moduladores de proteinquinasas
UA102516C2 (ru) Ингибиторы mcl-1 на основе 7-замещенных индолов